Systemic juvenile idiopathic arthritis

Autoimmunity Reviews

Volumn 12, Issue 1, 2012, Pages 56-59

  Martini, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Interleukin 1; Interleukin 6; Still's disease; Systemic juvenile idiopathic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

ABDOMINAL PAIN; ARTHRITIS; CLINICAL FEATURE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEVER; GENE EXPRESSION PROFILING; HEMATOPOIETIC CELL; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTOSIS; LYMPHADENOPATHY; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; MICROCYTIC ANEMIA; MYALGIA; NEUTROPHILIA; PATHOGENESIS; PHAGOCYTOSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; REVIEW; SPLENOMEGALY; STEROID THERAPY; SYNOVITIS; THROMBOCYTOSIS; UNSPECIFIED SIDE EFFECT;

ARTHRITIS, JUVENILE RHEUMATOID; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6;

EID: 84866862867     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.07.022     Document Type: Review

References (32)

1. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369:767-778.
2. Prakken B., Albani S., Martini A. Juvenile idiopathic arthritis. Lancet 2011, 377:2138-2149.
3. Mellins E.D., Macaubas C., Grom A.A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol 2011, 7:416-426.
4. Ravelli A., Magni-Manzoni S., Pistorio A., Besana C., Foti T., Ruperto N., et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr 2005, 146:598-604.
5. Martini A. It is time to rethink juvenile idiopathic arthritis classification and nomenclature. Ann Rheum Dis 2012, (Jun 7).
6. Wissler H. Subsepsis hyperergica. Monatsschr Kinderheilkd 1943, 94:1.
7. De Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G.R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991, 34:1158-1163.
8. Cazzola M., Ponchio L., De Benedetti F., Ravelli A., Rosti V., Beguin Y., et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood 1996, 87:4824-4830.
9. Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004, 113:1271-1276.
10. Martini A., Ravelli A., Di Fuccia G., Rosti V., Cazzola M., Barosi G. Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet 1994, 344:1052-1054.
11. De Benedetti F., Alonzi T., Moretta A., Lazzaro D., Costa P., Poli V., et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997, 99:643-650.
12. De Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?. J Rheumatol 1998, 25:203-207.
13. Verbsky J.W., White A.J. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004, 31:2071-2075.
14. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005, 201:1479-1486.
15. Frosch M., Ahlmann M., Vogl T., Wittkowski H., Wulffraat N., Foell D., et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:883-891.
16. Maeno N., Takei S., Nomura Y., Imanaka H., Hokonohara M., Miyata K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease. Arthritis Rheum 2002, 46:2539-2541.
17. de Jager W., Vastert S.J., Beekman J.M., Wulffraat N.M., Kuis W., Coffer P.J., et al. Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2009, 60:2782-2793.
18. Behrens E.M., Beukelman T., Paessler M., Cron R.Q. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34:1133-1138.
19. Gregorio A., Gambini C., Gerloni V., Parafioriti A., Sormani M.P., Gregorio S., et al. Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology 2007, 46:308-313.
20. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769.
21. Lovell D.J., Ruperto N., Goodman S., Reiff A., Jung L., Jarosova K., et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008, 359:810-820.
22. Ruperto N., Lovell D.J., Quartier P., Paz E., Rubio-Pérez N., Silva C.A., et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008, 372:383-391.
23. Quartier P., Taupin P., Bourdeaut F., Lemelle I., Pillet P., Bost M., et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093-1101.
24. Gattorno M., Piccini A., Lasigliè D., Tassi S., Brisca G., Carta S., et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008, 58:1505-1515.
25. Nigrovic P.A., Mannion M., Prince F.H., Zeft A., Rabinovich C.E., van Rossum M.A., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum 2011, 63:545-555.
26. Quartier P., Allantaz F., Cimaz R., Pillet P., Messiaen C., Bardin C., et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011, 70:747-754.
27. Ruperto N., Quartier P., Wulffraat N., Woo P., Ravelli A., Mouy R., et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012, 64:557-567.
28. Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat N, Horneff G, et al. Canakinumab in systemic juvenile idiopathic arthritis. submitted for publication.
29. Yokota S., Imagawa T., Mori M., Miyamae T., Aihara Y., Takei S., et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008, 371:998-1006.
30. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, et al. tocilizumab in systemic juvenile idiopathic arthritis: a randomized trial. submitted for publication.
31. Lehman T.J., Schechter S.J., Sundel R.P., Oliveira S.K., Huttenlocher A., Onel K.B. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multicenter study. J Pediatr 2004, 145:856-857.
32. De Kleer I.M., Brinkman D.M., Ferster A., Abinun M., Quartier P., Van Der Net J., et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004, 63:1318-1326.